Corcept Therapeutics

Corcept Therapeutics: Pioneering Cortisol Modulation for Serious Diseases Corcept Therapeutics is a publicly traded biopharmaceutical company focused on developing and commercializing drugs that regulate the effects of cortisol, a hormone impacting nearly 80% of the body's tissues. Our flagship product, Korlym® (mifepristone), is an FDA-approved treatment for hypercortisolism (Cushing's syndrome). We are currently expanding into oncology with a robust pipeline of investigational drugs targeting various serious diseases. We leverage a modern technology stack, including Amazon Web Services, Cloudflare CDN and Hosting, and various security technologies (DNSSEC, HSTS, reCAPTCHA) to ensure efficient operations and robust data security. Our engineering team utilizes technologies such as jQuery, while maintaining a commitment to innovation and collaboration. We offer a diverse range of opportunities across various departments, including marketing, sales, and clinical development, with several roles offering remote work options. Corcept fosters a culture of scientific excellence and patient-centricity. We value innovation, collaboration, and a dedication to improving the lives of those suffering from serious diseases. We are committed to advancing the possibilities of cortisol modulation as a therapeutic approach, and this is reflected in our extensive research and development efforts – boasting over 30 ongoing studies across several disease areas. Our dedication to expanding our knowledge in this field and advancing innovative solutions makes Corcept an exciting place to work. With a team of 251-500 employees and a history dating back to 1998, Corcept continues to grow, driven by both a strong intellectual property portfolio and a commitment to bringing life-changing medications to patients. Our recent expansion into oncology represents a major step in our growth trajectory.